Merck Ruling A Wake-Up Call For Patent Owners Facing PTAB

Law360, New York (December 18, 2015, 9:44 PM EST) -- The Federal Circuit’s decision Thursday upholding a Patent Trial and Appeal Board ruling that dietary supplement patents licensed by Merck KGaA are invalid as obvious provides a clear illustration of the risks for patents in inter partes reviews and how tough it is to get PTAB decisions overturned on appeal, attorneys say.

The initial PTAB decision in 2014 that Merck’s arguments for why the patents were not obvious could not overcome challenger Gnosis SpA’s evidence of obviousness is an indication that the board will be very closely scrutinizing the defenses used by patent owners in inter partes review, according to attorneys...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!